+

WO1995031220A1 - Agent de contraste pour imagerie par resonance magnetique - Google Patents

Agent de contraste pour imagerie par resonance magnetique Download PDF

Info

Publication number
WO1995031220A1
WO1995031220A1 PCT/JP1995/000894 JP9500894W WO9531220A1 WO 1995031220 A1 WO1995031220 A1 WO 1995031220A1 JP 9500894 W JP9500894 W JP 9500894W WO 9531220 A1 WO9531220 A1 WO 9531220A1
Authority
WO
WIPO (PCT)
Prior art keywords
iron oxide
contrast agent
group
magnetic
polysaccharide
Prior art date
Application number
PCT/JP1995/000894
Other languages
English (en)
Japanese (ja)
Inventor
Kazuo Yagi
Junji Nakamura
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Priority to AU24196/95A priority Critical patent/AU2419695A/en
Publication of WO1995031220A1 publication Critical patent/WO1995031220A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Definitions

  • the present invention relates to a magnetic resonance imaging (MRI) of a living body and a magnetic resonance contrast agent improved in its usefulness for diagnosis (hereinafter referred to as an MRI contrast agent), and particularly to an MRI contrast agent useful as an MR angiographic agent Agent.
  • MRI magnetic resonance imaging
  • an MRI contrast agent magnetic resonance contrast agent improved in its usefulness for diagnosis
  • Magnetic iron oxide fine particles having magnetism such as ferrite have attracted attention as MRI contrast agents because of their superparamagnetic properties.
  • magnetic iron oxide fine particles were hardly soluble as they were and had extremely high toxicity in intravenous administration, so that they could not be used for living bodies for medical purposes. Therefore, an MRI contrast agent in which magnetic iron oxide is coated with dextran or a dextran derivative is known.
  • magnetic iron oxide contrast agents such as "AM 1-25" manufactured by Advansed Magnetics Co., Ltd. exhibit superparamagnetic effects, and it has been known that coating with dextran reduces toxicity. I have.
  • dextran-based magnetic iron oxide contrast agents cannot stay in the circulatory system (vascular system) for a long time and are rapidly taken up by the liver or spleen.
  • the particle size is as large as 150 to 300 m, there are side effects such as hypotensive shock and allergic reaction.
  • hypotensive shock and allergic reaction For example, when an intravenous drip infusion is performed and an MRI image of the liver is taken one hour later, it is confirmed that a decrease in blood pressure, shock, and pulsation occurs during that time, and in some cases, death may occur.
  • the conventional contrast agent simply coats magnetic iron oxide with dextran, so that the bond between iron oxide and dextran is weak, and therefore, it is easily dissociated in blood, and the stability during heat sterilization is low.
  • the main object of the present invention is to enhance the signal intensity of intravascular blood flow, which is originally no signal on MR images, to image the blood flow, thereby enabling blood, heart, cerebral vascular system, abdominal vascular system,
  • An object of the present invention is to provide an MRI contrast agent that enables imaging of circulatory organs and organs such as lymphatic vessels, thereby facilitating diagnosis of lesions, and has high safety and stability.
  • Another object of the present invention is to provide a blood vessel which has a long residence time in a blood vessel, does not exude from a blood vessel to a tissue unlike conventional Gd-DTPA contrast agents, and makes the contrast between the blood vessel part and the tissue clear. It is to provide an MRI contrast agent for angiography.
  • the present inventors have conducted intensive research to solve the above-mentioned problems, and as a result, by using magnetic iron oxide fine particles as a core and coating this with a polysaccharide as an outer shell, MRI of cardiac and vascular systems, cine MR We have found the surprising fact that a T 1 -weighted image with the effect of increasing T 1 and decreasing T 2 in I is obtained.
  • the use of a polysaccharide having a specific functional group as a coating agent for the magnetic iron oxide fine particles increases the affinity of the iron oxide fine particles with water, which increases the biological affinity.
  • the adverse effects of long-term residence in blood vessels are reduced, the load on the living body is reduced, the safety is increased, and the specific functional groups of the outer polysaccharide are magnetic iron oxide fine particles. It shows high resilience and stability over a long period of time because it reacts with and binds tightly.
  • the present inventors have synthesized a magnetic iron oxide fine particle having an ultimate single domain structure, thereby producing a contrast agent for MRI in which fine particles having the property of a superparamagnetic material can be used as a strong paramagnetic material. succeeded in.
  • the NMR signal intensity is enhanced, and, for example, the heart, cerebral vascular system, abdominal vascular system, etc. can be imaged in white. Therefore, the MRI contrast agent of the present invention can be used as a T1 enhancer that enhances the T1 signal intensity by shortening the T1 relaxation time of a hydrogen atom in a living body.
  • iron oxide fine particles with a single domain structure have not existed. It was created for the first time.
  • the MRI contrast agent of the present invention has magnetic iron oxide fine particles having an average particle diameter of 2 to 20 nm and a single magnetic domain structure as a core, and the surface of the core is formed of a sulfone group (sulfate group), a ketone group, It is characterized by being coated with a polysaccharide having a functional group selected from the group consisting of an amino group, a carboxyl group and an alkyl group.
  • the MRI contrast agent of the present invention coats single-domain iron oxide fine particles with a polysaccharide, it is difficult for the fine particles to change over time together with the superparamagnetic effect, and is used for imaging heart and vascular organs with blood flow. That is, it can be suitably used as an MRI contrast agent for angiography.
  • the iron oxide fine particles are coated with the polysaccharide, problems of biological reactions and toxicity are solved, and affinity with blood and the like is further improved.
  • the MRI contrast agent of the present invention has an advantage in that absorption into organs such as the liver and spleen is delayed, so that it can stay in blood vessels for a long time.
  • the average particle size of the magnetic iron oxide fine particles used in the present invention is as fine as 2 to 20 nm, even if they stay in the blood vessel for a long time, there is no adverse effect such as a decrease in blood pressure and shock, and they are safe for living organisms. High in nature.
  • FIG. 1 is an explanatory diagram showing an MRI contrast agent of the present invention in which magnetic iron oxide fine particles are coated with a polysaccharide
  • FIG. 2 is a graph showing the magnetization curve of the chondroitin sulfate-monomagnetic iron oxide composite obtained in Production Example 1.
  • Fig. 3 is a transmission electron micrograph (TEM, magnification: 100,000 times) of the chondroitin sulfate-magnetic iron oxide complex obtained in Production Example 1.
  • Fig. 4 is a photograph showing MR angiography images near the heart and aorta of a rabbit taken under the same conditions using different contrast agents.
  • the right side of the photograph is an angiography image of the MRI contrast agent of the present invention, and the left side is an image. Shows an angiographic image of a conventional Gd-DTPA, respectively.
  • Examples of the magnetic iron oxide fine particles in the present invention include, for example, a general formula
  • M represents a divalent metal atom, and m is a number of 0 m 1.
  • Ferrite represented by Examples of the divalent metal atom include magnesium, calcium, manganese, iron, nickel, cobalt, copper, zinc, strontium, and barium.
  • M is a divalent magnetic iron oxide in the case of iron (e.g. magnetite F e 3 ⁇ 4, 7 - F e 2 0 3 , etc.) it is preferably used in the present invention.
  • the magnetic iron oxide fine particles in the present invention include those containing water of crystallization.
  • the magnetic iron oxide fine particles in the present invention have an average particle size of 2 to 20 nm, preferably 3 to 8 nm.
  • the single magnetic domain structure of the magnetic iron oxide fine particles refers to a structure having no magnetic domain wall and having only one magnetic domain like a normal magnetic material.
  • the reason for having no magnetic domain wall is that the average particle size of the magnetic iron oxide is extremely small to the molecular level as described above.
  • the residual magnetization shown in a typical magnetic hysteresis curve generated by the movement of the domain wall when an external magnetic field is applied as in a normal magnetic body does not appear (see the later-described embodiment).
  • the magnetic iron oxide fine particles having such a single magnetic domain structure act as a superparamagnetic substance or a strong paramagnetic substance, and thus can be suitably used as a T1 enhancer.
  • a water-soluble polysaccharide is preferable, and examples thereof include chondroitin 4-monosulfate, chondroitin 6-sulfate, hyaluronic acid, chitin, and heno.
  • examples include polysaccharides or mucopolysaccharides such as phosphorus, sialic acid, neuraminic acid, acetylhexosamine, inulin, agarose, dextransulfonic acid, and N-cetylglycosamine derivatives.
  • a sulfone group substituted, amino Moto ⁇ conversion, an alkyl group substituted or ketone group e.g., - CH 2 -C0-CH 2 CH 3,
  • a dextrin substituted with —CH 2 —0C0—N 2 or the like can also be suitably used.
  • alkyl group examples include an alkyl group having 1 to 6 carbon atoms such as a methyl group, an ethyl group, a propyl group, an isopropyl group, an n-butyl group, a t-butyl group, a pentyl group and a hexyl group.
  • these polysaccharides have a number average molecular weight in the range of about 500 to 300,000, preferably about 1000 to 50,000, more preferably about 150 to 30,000. is there.
  • the polysaccharide may be used as a mixture with various oligosaccharides (such as glucose, maltose, lactose, cellobiose, maltotriose, and melibiose) and pullulan.
  • a function as a therapeutic agent can be imparted to the polysaccharide by containing various receptors having specificity for accumulation in abnormal cells such as tumor cells.
  • the receptor include, for example, various monoclonal antibodies, various proteins, and immune-related agents (immune cell activation and activation materials). This is useful, for example, in diagnosing and treating tumors, as well as inducing killer cells.
  • an aqueous sol consisting only of magnetic iron oxide fine particles is prepared and then reacted with a polysaccharide, and the first method is a one-step synthesis in the presence of the polysaccharide.
  • the first method is a one-step synthesis in the presence of the polysaccharide.
  • an aqueous bull made of only magnetic iron oxide fine particles is prepared.
  • the method for preparing the aqueous sol include a co-precipitation method with a zinc ion exchange resin method and the like.
  • ferrous and ferric salts are mixed at a molar ratio of 1: 3
  • To 2 About 0 includes in the order of one ratio and the 1-2 moles of aqueous, N a OH, then mixed as KOH, NH 4 ⁇ ⁇ 1 like base and a 11 is about 7 to 1 2, If necessary, heat and ripen.Then, the magnetic iron oxide formed is separated, washed with water, redispersed in water, and a mineral acid such as hydrochloric acid is added until the pH of the solution becomes about 1 to 3. A magnetic iron oxide aqueous solution can be obtained.
  • an about 0.1 to 2 mol aqueous solution containing a ferrous salt and a ferric salt in a molar ratio of about i: 2 is stirred into a strongly basic exchange resin slurry.
  • a mineral acid such as hydrochloric acid is added until the pH becomes about 1 to 3, and then the resin is filtered off to obtain a magnetic iron oxide aqueous solution. it can.
  • aqueous sols may be purified or reduced by filtration, ultrafiltration, centrifugation or the like as necessary.
  • the reaction between the aqueous magnetic iron oxide aqueous solution and the polysaccharide is usually performed by mixing these at a predetermined ratio and heating.
  • the ratio of the magnetic iron oxide aqueous sol to the polysaccharide is about 1 by weight. : 1 to 1: About 6 is sufficient.
  • the reaction may be carried out at a temperature from room temperature to about 120 ° C. for about 10 minutes to 10 hours, and usually, heating and refluxing for about 1 hour is sufficient.
  • the concentration of the magnetic iron oxide in the reaction solution is usually about 0.1 to 1 OwZv%, preferably about 1 to 5 w / v% as iron.
  • a purification operation for separating unreacted polysaccharides and low molecular weight compounds is performed by using a known means such as ultrafiltration to obtain an aqueous solution having a predetermined purity and concentration.
  • a solvent such as methanol, ethanol, or acetone is added to preferentially precipitate and precipitate the magnetic iron oxide fine particle-polysaccharide complex, which is separated, and then the precipitate is re-dissolved in water, and The mixture is dialyzed and, if necessary, concentrated under reduced pressure to obtain an aqueous solution of the above complex. Then, if necessary, centrifugation, filtration, pH adjustment and the like may be performed.
  • the MRI contrast agent of the present invention obtained by caulking has an average particle size of about 30 to 200 nm, and the magnetic iron oxide fine particles as the core have an average particle size of about 2 to 20 nm. These particle sizes are measured by the dynamic light scattering method.
  • the magnetization of the MRI contrast agent at 1 Tesla is usually in the range of about 20 to 150 emu / g of iron.
  • a second method for preparing the MRI contrast agent of the present invention comprises, in the presence of a polysaccharide having a specific functional group, a mixed aqueous solution of a ferrous salt of iron (III) and a salt of iron (III) and an aqueous solution of a base. These are mixed and reacted.
  • the order of adding the polysaccharide, the mixed iron salt aqueous solution and the base aqueous solution is not particularly limited.
  • the mixed iron salt aqueous solution is prepared by dissolving a ferrous salt and a ferric salt in a molar ratio of about 1: 4 to 3: 1, preferably about 1: 3 to 1: 1, in an aqueous medium.
  • the concentration of the aqueous iron salt solution is usually about 0.1 to 3 mol, preferably about 0.5 to 2 mol.
  • iron salts include salts with mineral acids such as hydrochloric acid, sulfuric acid, and nitric acid.
  • the base include alkali metal hydroxides such as Na ⁇ H and K ⁇ H, and amines such as ammonium nitrate, triethylamine, and trimethylamine.If necessary, a mixture of two or more kinds may be used. You can.
  • the amount of polysaccharide used should be about 1 to 15 times, preferably 3 to 10 times, based on the weight of the iron salt used.
  • the mixture After adjusting the pH by adding a base or an acid as necessary, the mixture is heated at a temperature of about 60 to 120 ° C. for about ⁇ 0 to 5 hours, preferably for about 1 hour. The reaction is caused by flowing. The obtained reaction solution is purified in the same manner as in the first method, and if necessary, pH adjustment, concentration, and filtration are performed.
  • the particle size of the magnetic iron oxide fine particles to be generated is set to 2 to
  • the particle size of the formed composite can be controlled by adjusting the reaction time and the reaction temperature.
  • the ratio of the polysaccharide to the magnetic iron oxide fine particles is not particularly limited, but generally, the polysaccharide is about 0.1 to 5 parts by weight, preferably 0 to 5 parts by weight per 1 part by weight of iron in the magnetic iron oxide. It can be contained in the range of 2 to 3 parts by weight.
  • ferrous salt is used as another divalent metal salt such as magnesium, calcium, manganese, niggel, cobalt, copper, or the like. It can be replaced with one or more salts, such as zinc.
  • the polysaccharide and the magnetic iron oxide fine particles react with each other by the above-described method to form a compound bonded to each other.
  • it has a form in which magnetic iron oxide fine particles are used as a core, and the surface thereof is firmly covered with a polysaccharide. This means that, for example, when the reaction product is fractionated on a gel column, an elution peak is observed on the higher polymer side than the elution position of the polysaccharide, and both sugar and iron are detected by analyzing the force and the peak. ing.
  • T 1 relaxation ability of the MR I contrast agents of the invention one crotch about 2 ⁇ 5 0 (sec - mM) 1 , is good Mashiku is about 3 ⁇ 3 O (sec 'mM) _ 1.
  • the T2 mitigation capacity is generally about 3 ⁇
  • the MRI contrast agent of the present invention is used in the form of an aqueous sol.
  • concentration of the magnetic iron oxide fine particle-polysaccharide complex in the aqueous sol can be set as appropriate in consideration of the dosage to the living body, etc. Approximately 90 ax mol / ⁇ to 20 ⁇ mol (90 nmol / to 720 nmol / m), preferably about 180 / ⁇ to 360 mol / ⁇ is sufficient.
  • inorganic salts such as sodium chloride, monosaccharides such as glucose, sugar alcohols such as mannite, sorbitol, and organic acid salts such as acetate, lactate, citrate, and tartaric acid , A phosphate buffer, a Tris buffer and the like can be appropriately added.
  • the MRI contrast agent of the present invention uses magnetic iron oxide in the form of ultrafine particles, and the outer shell polysaccharide has a specific functional group. Accordingly, it can be used as a powerful paramagnetic T1 contrast agent.
  • the outer shell polysaccharide has an elastic structure in the form of hair balls or coils, and if it is elongated, it has a very long molecular structure. It is not easily degraded even in the living body and can exist as a saccharide in blood for a long time. That is, as shown in FIG. 1, the MRI contrast agent of the present invention has magnetic iron oxide fine particles 1 as a core, and a large number of polysaccharide chains 2 are firmly attached to the surface of the magnetic iron oxide fine particles 1 so as to cover the surface. Is bound to. Therefore, the iron oxide fine particles 1 and the polysaccharide chains 2 are not easily dissociated in blood, and can be present in blood for a long time.
  • the amount of the MRI contrast agent of the present invention is about 1-2 cc Zkg by intravenous administration in the case of an aqueous sol having an iron equivalent concentration of 180 to 360 mol ⁇ . Is appropriate.
  • a typical dose in terms of iron is about 5 ⁇ moI to 40 ⁇ / i, preferably about 10 mol Z ⁇ to 20 mol Z, in terms of iron.
  • Suitable administration methods include intravenous, intraarterial, intravesical, intramuscular, and subcutaneous injection and injection, but oral administration and intestinal administration are also possible.
  • the MRI contrast agent of the present invention has a characteristic that it stays in the bloodstream for a long time and is hardly absorbed by organs such as the liver and ⁇ , and can stay in the vasculature, which is a characteristic of the sugar agent, for a long time. That During recognition, polysaccharides surface sulfonic group is an outer shell by the presence of certain functional groups, such as (one S 0 3 H, sulphate group), a ketone group, a saccharification coalescing recognition of biological defense mechanisms And delay the decomposition and absorption of magnetic iron oxide.
  • MRI imaging can be suitably performed even for an organ that requires a relatively long time to reach the contrast agent, and that an examination time can be easily set.
  • Blood vessels are mainly targeted as organs to be imaged. Unlike conventional Gd-chelate contrast agents, they do not penetrate blood vessels and are suitable for enhancing contrast between blood vessels and surrounding tissues.
  • the liver, lymph vessels, brain, spleen, and digestive tract can be imaged.
  • the MRI contrast agent of the present invention has safety such as being able to inject a bolus intravenously without causing a decrease in blood pressure or shock.
  • the MRI contrast agent of the present invention can make the T1 relaxation ability larger than the T2 relaxation ability by making the particle size of magnetic iron oxide extremely fine to the size of the ultimate single domain fine particles.
  • the MRI contrast agent of the present invention is extremely effective in the latest equipment such as high-speed MRI imaging, and greatly facilitates the diagnosis of myocardial infarction, cerebral infarction, cancer and vascular lesions. The effect can be expected.
  • the MRI contrast agent of the present invention When the MRI contrast agent of the present invention is administered intravascularly, it can enhance the signal intensity of the vascular part in MR angiodara phylla and cause white contrast. It can also be used as a liver MRI contrast agent since it reduces the liver signal after a certain period of time after administration.
  • the MRI contrast agent of the present invention can be easily administered, has high stability as a preparation, and has high safety. Furthermore, the MRI contrast agent of the present invention has a long residence time in a blood vessel and has no exudation outside the blood vessel, so that the blood vessel can be contrasted and the examination time is long. Is easy to set.
  • the pH was adjusted to 11 by dropwise addition of 3 N sodium hydroxide with stirring. Then, 6N hydrochloric acid was added dropwise to adjust the pH to 6.9. In this state, the temperature of the solution was kept at 100 ° C., heated for 1 hour, and then cooled to 2 (TC, and then centrifuged at 3000 rpm for 30 minutes to separate a supernatant.
  • the magnetic measurement result of the obtained chondroitin sulfate monomagnetic iron oxide complex is shown.
  • a hysteresis curve was drawn using a sample vibrating magnetometer (VMS: Vibrating Sample magnetometer) manufactured by Toei Kogyo Co., Ltd., and the saturation magnetization was determined from this curve.
  • VMS Vibrating Sample magnetometer
  • As the measurement sample a sample (S1 to S5) randomly sampled from the fine powder particles obtained by drying the aqueous bull was used and packed in a measurement capsule, and the result was converted to the value per 1 g of the sample. did.
  • Iron oxide fine particles (S6) not coated with chondroitin sulfate were similarly measured and compared.
  • FIG. 2 shows the magnetization curves of the samples S1 to S5.
  • Table 1 shows the saturation magnetization of samples S1 to S6. table 1
  • FIG. 2 clearly shows that the resulting composite is a superparamagnetic material.
  • this magnetization curve follows the same locus with respect to the reversal of the external magnetic field, indicating that the obtained iron oxide fine particles have a single magnetic domain structure.
  • iron oxide fine particles having the same initial magnetization curve, demagnetization curve, and magnetization curve are considered to have no magnetic anisotropy while being a superparamagnetic material, and have no remanent magnetization and a low coercive force.
  • the particle size of the chondroitin sulfate-magnetic iron oxide complex was measured by a dynamic light scattering method using a dynamic light scattering light intensity system, and the particle size distribution was determined by histogram method analysis. The results are shown in Table 2.
  • Fig. 3 shows a transmission electron micrograph (TEM, magnification: ⁇ 1,000) of the chondroitin sulfate-monomagnetic iron oxide complex.
  • TEM transmission electron micrograph
  • the pH was adjusted to 11 by dropwise addition of 3 N sodium hydroxide with stirring. Then, 6 N hydrochloric acid was added dropwise to adjust the pH to 6.9. In this state, the solution was heated for 1.5 hours while keeping the temperature of the solution at 100, and then cooled to 14, and then centrifuged at 3000 rpm for 30 minutes to separate a supernatant. 310 ml of acetone was added to 400 ml of the supernatant, and centrifuged at 2000 rpm to obtain a precipitate of the complex. The precipitate was dissolved in 120 ml of water, adjusted to pH 8 with 3 N sodium hydroxide, and dialyzed with running water for about 15 hours.
  • Test example 1 in vivo MR imaging
  • Table 3 shows the T1-weighted image
  • Table 4 shows the signal intensity for each concentration when the proton density-weighted image was captured.
  • Test example 2 in vivo MR imaging
  • FIG. 4 shows an MR angiography image around the rabbit heart and aorta in comparison with the MRI contrast agent of the present invention and Gd-DTPA.
  • the right of the photograph is an image obtained by using the MRI contrast agent of the present invention (contrast agent obtained in Production Example 1), and the left is an image obtained by using a conventional Gd-DTPA (trade name: Magnepist, manufactured by Schering AG).
  • test conditions are as follows.
  • TR 40 ms e c.
  • TE 10 ms e c.
  • the MRI contrast agent of the present invention can clearly display a blood vessel image that cannot be seen with a normal contrast agent, and its contribution to future medical treatment is immeasurable.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un agent de contraste pour imagerie par résonance magnétique (agent de contraste pour I.R.M.) qui comprend de fines particules d'oxyde de fer magnétiques, dont le diamètre moyen est de 2-20 nm et qui possède des propriétés d'un seul domaine magnétique formé par le noyau, la surface de celui-ci étant revêtue d'un polysaccharide possédant des groupes fonctionnels choisis parmi sulfone, cétone, amino, carboxyle et alkyle. Lorsqu'il est injecté dans un vaisseau sanguin, pour la réalisation d'une angiographie par résonance magnétique, ledit agent de contraste augmente l'intensité du signal provenant du vaisseau sanguin pour donner ainsi une image blanche. Cet agent peut également être utilisé dans le foie comme agent de contraste pour I.R.M. car il peut réduire l'intensité du signal provenant du foie après écoulement d'un temps donné à partir de l'injection. L'agent de contraste présenté est facile à injecter et constitue une préparation pharmaceutique très stable et très sûr. En outre, il peut rester longtemps dans un vaisseau sanguin, sans en exsuder, ce qui permet d'obtenir une augmentation du contraste dans ledit vaisseau et facilite la détermination d'une durée d'examen adéquate.
PCT/JP1995/000894 1994-05-12 1995-05-10 Agent de contraste pour imagerie par resonance magnetique WO1995031220A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24196/95A AU2419695A (en) 1994-05-12 1995-05-10 Contrast medium for magnetic resonance imaging

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9873594 1994-05-12
JP6/98735 1994-05-12

Publications (1)

Publication Number Publication Date
WO1995031220A1 true WO1995031220A1 (fr) 1995-11-23

Family

ID=14227773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/000894 WO1995031220A1 (fr) 1994-05-12 1995-05-10 Agent de contraste pour imagerie par resonance magnetique

Country Status (2)

Country Link
AU (1) AU2419695A (fr)
WO (1) WO1995031220A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6123920A (en) * 1996-01-10 2000-09-26 Nycomed Imaging As Superparamagnetic contrast media coated with starch and polyalkylene oxides
US6423296B1 (en) 1996-01-10 2002-07-23 Amersham Health As Constrast media
WO2005087367A1 (fr) * 2004-03-15 2005-09-22 Hitachi Maxell, Ltd. Particule composite magnétique et son procédé de production
JP2005296942A (ja) * 2004-03-15 2005-10-27 Hitachi Maxell Ltd 磁性複合粒子およびその製造方法
AU2001294068B2 (en) * 2000-10-16 2005-12-22 Consejo Superior De Investigaciones Cientificas Nanoparticles
JP2008037856A (ja) * 2006-07-10 2008-02-21 Keio Gijuku Ｍｒｉプローブ
EP1952919A2 (fr) 2007-02-02 2008-08-06 Fujifilm Corporation Nanoparticules magnétiques et composition colloïde aqueuse les contenant
KR100949465B1 (ko) 2008-02-20 2010-03-29 전남대학교산학협력단 만난이 코팅된 초상자성 산화철 나노입자, 이의 제조방법및 이를 포함하는 간질환 진단용 조영제
WO2011062217A1 (fr) 2009-11-20 2011-05-26 戸田工業株式会社 Poudre de microparticules d'oxyde de fer magnétique, dispersion aqueuse contenant des particules magnétiques et son procédé de fabrication
JP2011241194A (ja) * 2010-05-20 2011-12-01 Cota Co Ltd 育毛剤
KR101303567B1 (ko) 2011-03-08 2013-09-23 주식회사 인트론바이오테크놀로지 카르복실기가 도입된 만난으로 코팅된 자기공명영상 조영제 및 그것의 제조 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500196A (ja) * 1986-07-03 1989-01-26 アドバンスド　マグネティックス，インコーポレーテッド 臨床用途に使用される生物分解性超常磁性物質
WO1989003675A1 (fr) * 1987-10-26 1989-05-05 Carbomatrix Ab Particules superparamagnetiques, moyen de production de telles particules et leur utilisation
EP0516252A2 (fr) * 1991-05-28 1992-12-02 INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN Particules monocristallines d'oxyde ferrique pour application en diagnostique et thérapie
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01500196A (ja) * 1986-07-03 1989-01-26 アドバンスド　マグネティックス，インコーポレーテッド 臨床用途に使用される生物分解性超常磁性物質
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
WO1989003675A1 (fr) * 1987-10-26 1989-05-05 Carbomatrix Ab Particules superparamagnetiques, moyen de production de telles particules et leur utilisation
EP0516252A2 (fr) * 1991-05-28 1992-12-02 INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN Particules monocristallines d'oxyde ferrique pour application en diagnostique et thérapie

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6123920A (en) * 1996-01-10 2000-09-26 Nycomed Imaging As Superparamagnetic contrast media coated with starch and polyalkylene oxides
US6423296B1 (en) 1996-01-10 2002-07-23 Amersham Health As Constrast media
US8080431B2 (en) 2000-10-16 2011-12-20 Midatech Limited Nanoparticles
US7364919B2 (en) 2000-10-16 2008-04-29 Midatech Limited Nanoparticles
AU2001294068B2 (en) * 2000-10-16 2005-12-22 Consejo Superior De Investigaciones Cientificas Nanoparticles
US8790934B2 (en) 2000-10-16 2014-07-29 Consejo Superior De Investigaciones Cientificas Nanoparticles
WO2005087367A1 (fr) * 2004-03-15 2005-09-22 Hitachi Maxell, Ltd. Particule composite magnétique et son procédé de production
JP2005296942A (ja) * 2004-03-15 2005-10-27 Hitachi Maxell Ltd 磁性複合粒子およびその製造方法
JP2008037856A (ja) * 2006-07-10 2008-02-21 Keio Gijuku Ｍｒｉプローブ
EP1952919A2 (fr) 2007-02-02 2008-08-06 Fujifilm Corporation Nanoparticules magnétiques et composition colloïde aqueuse les contenant
KR100949465B1 (ko) 2008-02-20 2010-03-29 전남대학교산학협력단 만난이 코팅된 초상자성 산화철 나노입자, 이의 제조방법및 이를 포함하는 간질환 진단용 조영제
WO2011062217A1 (fr) 2009-11-20 2011-05-26 戸田工業株式会社 Poudre de microparticules d'oxyde de fer magnétique, dispersion aqueuse contenant des particules magnétiques et son procédé de fabrication
JP2011126876A (ja) * 2009-11-20 2011-06-30 Toda Kogyo Corp 磁性酸化鉄微粒子粉末、磁性粒子含有水分散体およびその製造方法
US9127168B2 (en) 2009-11-20 2015-09-08 Toda Kogyo Corporation Magnetic iron oxide fine particles, and magnetic particle-containing water dispersion and process for producing the same
JP2011241194A (ja) * 2010-05-20 2011-12-01 Cota Co Ltd 育毛剤
KR101303567B1 (ko) 2011-03-08 2013-09-23 주식회사 인트론바이오테크놀로지 카르복실기가 도입된 만난으로 코팅된 자기공명영상 조영제 및 그것의 제조 방법

Also Published As

Publication number Publication date
AU2419695A (en) 1995-12-05

Similar Documents

Publication Publication Date Title
US5328681A (en) Composition comprising magnetic metal oxide ultrafine particles and derivatized polysaccharides
US5069216A (en) Silanized biodegradable super paramagnetic metal oxides as contrast agents for imaging the gastrointestinal tract
JP3337075B2 (ja) 小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体
US4951675A (en) Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
US4827945A (en) Biologically degradable superparamagnetic materials for use in clinical applications
AU652829B2 (en) Melanin-based agents for image enhancement
US4770183A (en) Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5219554A (en) Hydrated biodegradable superparamagnetic metal oxides
US10987436B2 (en) Superparamagnetic nanoparticles as a contrast agent for magnetic resonance imaging (MRI) of magnetic susceptibility (T2*)
JPH07500823A (ja) 医療診断イメージング用処理アパタイト粒子
US20060093555A1 (en) Imaging inflammatory conditions using superparamagnetic iron oxide agents
Xue et al. 99mTc-labeled iron oxide nanoparticles for dual-contrast (T 1/T 2) magnetic resonance and dual-modality imaging of tumor angiogenesis
WO2013150118A1 (fr) Dispersion de nanoparticules magnétiques, sa préparation et usage diagnostique et thérapeutique
WO1995031220A1 (fr) Agent de contraste pour imagerie par resonance magnetique
JP2001512144A (ja) 組織の潅流の造影剤増強磁気共鳴撮像法
Wallace et al. Synthesis and preliminary evaluation of MP‐2269: a novel, nonaromatic small‐molecule blood‐pool MR contrast agent
RU2530762C2 (ru) Способ диагностики мультиформной глиобластомы с помощью мрт
JPH10120597A (ja) リンパ節高集積性コロイド粒子
Kroft et al. Equilibrium phase MR angiography of the aortic arch and abdominal vasculature with the blood pool contrast agent CMD‐A2‐Gd‐DOTA in pigs
KR101080581B1 (ko) 자기공명영상 ｔ1 및 ｔ2 이중 조영성 산화철/산화망간 혼성나노입자 및 이의 제조 방법
WO2021189121A1 (fr) Nanoparticules paramagnétiques, procédé de fabrication et utilisation de celles-ci comme produit de contraste en imagerie par résonance magnétique
KR101417869B1 (ko) 인산염이 결합된 고분자로 코팅된 산화철 나노입자를 포함하는 조영제 및 이의 제조방법
CN114042172A (zh) pH响应性T1-T2双激活纳米探针及其制备方法和应用

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载